在美展示成果，“中国开始领跑”

Core Insights - Chinese research team showcased innovative cardiac intervention device at the global transcatheter cardiovascular therapy conference in San Francisco, indicating China's shift from "follower" to "leader" in structural heart disease intervention [1] Group 1: Clinical Data and Innovation - The "J-VALVE TF transcatheter aortic valve system" demonstrated superior clinical outcomes, including lower rates of post-operative cardiac mortality and third-degree atrioventricular block compared to international counterparts [1] - The device features a unique patented "movable positioning component" that addresses key challenges in treating aortic regurgitation, such as valve anchoring difficulties and high rates of paravalvular leak [1] Group 2: Conference Overview - The conference, hosted by the American College of Cardiology, is one of the largest and most influential academic meetings in the field of transcatheter cardiovascular interventions, attracting over ten thousand participants from more than 100 countries and regions [2]